Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Vyvgart efgartigimod alfa Generalized myasthenia gravis (gMG) Reimburse with clinical criteria and/or conditions Complete
Vyxeos daunorubicin and cytarabine Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Vyzulta latanoprostene bunod Open-angle glaucoma or ocular hypertension Reimburse with clinical criteria and/or conditions Complete
Wainua eplontersen Polyneuropathy in hereditary transthyretin-mediated amyloidosis Active
Wakix pitolisant hydrochloride Narcolepsy Do not reimburse Complete
Waymade-Trientine trientine hydrochloride Wilson's Disease Reimburse with clinical criteria and/or conditions Complete
Wegovy semaglutide Weight management Do not reimburse Complete
Wegovy semaglutide weight management Pending
Welireg belzutifan von Hippel-Lindau disease-associated tumours Reimburse with clinical criteria and/or conditions Complete
Welireg belzutifan advanced renal cell carcinoma (RCC) Pending